News
ONC
298.16
-0.25%
-0.74
BeOne Medicines: FDA grants Priority Review to sBLA for tevimbra/ziihera combo
TipRanks · 22m ago
FDA Grants Priority Review To BeOne Medicines' Supplemental Biologics License Application For Tevimbra (Tislelizumab) In Combination With Ziihera (Zanidatamab) And Chemotherapy For Untreated Unresectable Locally Advanced/Metastatic HER2-positive Gastric, Gastroesophageal Junction, Or Esophageal Adenocarcinoma
Benzinga · 41m ago
FDA grants priority review to BeOne’s TEVIMBRA combo in first-line HER2+ GEA
PUBT · 41m ago
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA
Barchart · 5h ago
BeOne Medicines AG announces annual shareholder meeting
PUBT · 23h ago
BeOne Medicines announces 2026 annual general meeting record date
PUBT · 23h ago
Weekly Report: what happened at ONC last week (0420-0424)?
Weekly Report · 2d ago
BeOne Medicines to report first-quarter results, host management webcast
PUBT · 04/22 10:03
Weekly Report: what happened at ONC last week (0413-0417)?
Weekly Report · 04/20 09:15
Johnson & Johnson: Why I See Downside Ahead
Seeking Alpha · 04/17 14:42
Here are the major earnings after the close Wednesday
Seeking Alpha · 04/15 14:00
BeiGene Q1 2026 Earnings Preview
Seeking Alpha · 04/14 21:35
BeOne Medicines publishes 2025 Responsible Business and Sustainability Report
PUBT · 04/14 13:07
BeOne Medicines publishes 2025 annual report
PUBT · 04/14 12:54
Analysts Conflicted on These Healthcare Names: Johnson & Johnson (JNJ), BeOne Medicines (ONC) and Helus Pharma (HELP)
TipRanks · 04/13 09:50
Weekly Report: what happened at ONC last week (0406-0410)?
Weekly Report · 04/13 09:16
BeOne Medicines SVP, General Counsel Henry Lee Chan disposes of shares worth $103,448
Reuters · 04/10 21:40
BeOne wins China approval for Amgen’s lung cancer drug Imdelltra
Seeking Alpha · 04/10 13:03
BeOne Medicines (ONC) Receives a Buy from Truist Financial
TipRanks · 04/10 02:25
Should FDA Orphan Drug Nod And Analyst Shifts Require Action From BeOne Medicines (ONC) Investors?
Simply Wall St · 04/09 02:40
More
Webull provides a variety of real-time ONC stock news. You can receive the latest news about BeOne Medicines Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About ONC
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.